Obtaining real-world evidence: the Salford Lung Study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 24603195.
- Also identified by DOI 10.1136/thoraxjnl-2014-205259 and PMC identifier 4251297.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We need to assess clinical treatments in real-life settings outside of randomised controlled trials (RCTs). Pragmatic RCT (pRCT) data can supplement RCTs by providing effectiveness information to support healthcare decisions. Electronic health records can facilitate concurrent safety monitoring and data collection without direct patient contact for large randomised study populations in pRCTs. The Salford Lung Study is the world's first phase III pRCT in asthma and chronic obstructive pulmonary disease (COPD), which aims to randomise over 7000 patients. This paper describes the hurdles overcome and the enormous effort and resource required to establish this comparative effectiveness study of a prelicence intervention. HZC115151 ASTHMA STUDY CLINICALTRIALSGOV REGISTRATION: NCT01706198 COPD STUDY CLINICALTRIALSGOV REGISTRATION: NCT01551758.
Medical subject headings
- Adrenergic beta-Agonists
- Asthma
- Glucocorticoids
- Pulmonary Disease, Chronic Obstructive
- Randomized Controlled Trials as Topic